Lys-MDA
Also called (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
Overview
Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland. A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024. The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.[1–6] WP
Drug class
Serotonin–norepinephrine–dopamine releasing agent Serotonin 5-HT2 receptor agonist Entactogen Empathogen Serotonergic psychedelic Hallucinogen Stimulant WP
From the Wikipedia article's infobox.
Chemistry
Mixing
For best safety practice, don't mix this drug with other stimulants.
Why: vasoconstriction, heart rate and blood pressure. PsychonautWiki says:
- “... may be dangerous to combine with other stimulants ... as they can increase one's heart rate and blood pressure to dangerous levels.” (PsychonautWiki, dangerous interactions table, "Stimulants" row, revision 148925)
- “Vasoconstriction can be described as a narrowing of the veins and blood vessels which results from a contraction of their muscular wall.” (PsychonautWiki, Vasoconstriction, revision 170337)
- “... it can also occur under the influence of traditional stimulants such as methamphetamine, caffeine, and MDMA.” (PsychonautWiki, Vasoconstriction, revision 170337)
- “Increased blood pressure is most commonly induced under the influence of heavy dosages of vasoconstricting compounds, such as traditional stimulants and stimulating psychedelics.” (PsychonautWiki, Increased blood pressure, revision 152273)
Quotes from PsychonautWiki, CC BY-SA 4.0.
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Journal / agency Straumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, Eckert A, Luethi D, Rudin D, Liechti ME. Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants. Neuropsychopharmacology. September 2025. doi:10.1038/s41386-025-02248-3 · PMID 40999236 · PMC12708835
- Other Buntz B. MindMed announces Phase 1 study of MDMA-like substances. 21 September 2022
- Other MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances. 20 September 2022
- Other Novel Safrylamine derivatives having prodrug properties
- Other Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof
- Other ClinicalTrials.gov. 13 August 2024
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.